FDA Approves Glaukos' New Drug Application for iDose TR
By Dean Seal
Glaukos said federal regulators have approved a new drug application for iDose TR, a treatment for ocular hypertension and open-angle glaucoma.
The ophthalmic medical technology and pharmaceutical company said Thursday morning that the Food and Drug Administration approved the application for a single administration per eye of iDose TR for the reduction of intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
Glaukos said iDose TR is designed to continuously deliver therapeutic levels of a proprietary formulation of travoprost inside the eye for extended periods of time.
The approval is based on two pivotal Phase 3 trials that successfully achieved their primary efficacy endpoints through three months and demonstrated a favorable tolerability and safety profile through 12 months.
Glaukos intends to start initial commercial launch activities for iDose TR in the latter part of the first quarter of 2024.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
December 14, 2023 07:49 ET (12:49 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom
-
Albemarle Earnings: We Expect Improved Results In the Rest of Year Following Cyclically Low Profits